cLRT-Mod: An efficient methodology for pharmacometric model-based analysis of longitudinal phase II dose finding studies under model uncertainty

被引:4
|
作者
Buatois, Simon [1 ,2 ]
Ueckert, Sebastian [3 ]
Frey, Nicolas [2 ]
Retout, Sylvie [2 ]
Mentre, France [1 ]
机构
[1] Univ Paris Diderot, INSERM, IAME, UMR 1137, Paris, France
[2] F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Pharmaceut Sci, Roche Innovat Ctr Basel, Basel, Switzerland
[3] Uppsala Univ, Dept Pharmaceut Biosci, Uppsala, Sweden
关键词
dose‐ response; effects model; LRT; MCP‐ Mod; model averaging; nonlinear mixed; MIXED-EFFECTS MODELS; DISEASE PROGRESSION; ALZHEIMERS-DISEASE; SELECTION; TRIALS; TOFOGLIFLOZIN; GLICLAZIDE;
D O I
10.1002/sim.8913
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Within the challenging context of phase II dose-finding trials, longitudinal analyses may increase drug effect detection power compared to an end-of-treatment analysis. This work proposes cLRT-Mod, a pharmacometric adaptation of the MCP-Mod methodology, which allows the use of nonlinear mixed effect models to first detect a dose-response signal and then identify the doses for the confirmatory phase while accounting for model structure uncertainty. The method was evaluated through extensive clinical trial simulations of a hypothetical phase II dose-finding trial using different scenarios and comparing different methods such as MCP-Mod. The results show an increase in power using cLRT with longitudinal data compared to an EOT multiple contrast tests for scenarios with small sample size and weak drug effect while maintaining pre-specifiability of the models prior to data analysis and the nominal type I error. This work shows how model averaging provides better coverage probability of the drug effect in the prediction step, and avoids under-estimation of the size of the confidence interval. Finally, for illustration purpose cLRT-Mod was applied to the analysis of a real phase II dose-finding trial.
引用
收藏
页码:2435 / 2451
页数:17
相关论文
共 34 条
  • [21] A Bayesian Dynamic Model-Based Adaptive Design for Oncology Dose Optimization in Phase I/II Clinical Trials
    Qiu, Yingjie
    Li, Mingyue
    PHARMACEUTICAL STATISTICS, 2025, 24 (02)
  • [22] Model-based phase II dose selection of c-Met inhibitor MSC2156119J
    Xiong, Wenyuan
    El Bawab, Samer
    Bladt, Friedhelm
    Meyring, Michael
    Klevesath, Manfred
    Falchook, Gerald
    Hone, David
    Johne, Andreas
    Girard, Pascal
    CANCER RESEARCH, 2015, 75
  • [23] Practical model-based dose finding in early-phase clinical trials - Optimizing tissue plasminogen activator dose for treatment of ischemic stroke in children
    Whelan, Harry T.
    Cook, John D.
    Amlie-Lefond, Catherine M.
    Hovinga, Collin A.
    Chan, Anthony K.
    Ichord, Rebecca N.
    deVeber, Gabrielle A.
    Thall, Peter F.
    STROKE, 2008, 39 (09) : 2627 - 2636
  • [24] Community and Campus COVID-19 Risk Uncertainty Under University Reopening Scenarios: Model-Based Analysis
    Benneyan, James
    Gehrke, Christopher
    Ilies, Iulian
    Nehls, Nicole
    JMIR PUBLIC HEALTH AND SURVEILLANCE, 2021, 7 (04):
  • [25] Many Flavors of Model-Based Meta-Analysis: Part II - Modeling Summary Level Longitudinal Responses
    Boucher, Martin
    Bennetts, Meg
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2018, 7 (05): : 288 - 297
  • [26] A model-based methodology for the analysis and design of atomic layer deposition processes-Part II: Experimental validation and mechanistic analysis
    Holmqvist, A.
    Torndahl, T.
    Stenstrom, S.
    CHEMICAL ENGINEERING SCIENCE, 2013, 94 : 316 - 329
  • [27] Model-based predictions of expected anti-tumor response and survival in phase III studies based on phase II data of an investigational agent.
    Claret, L.
    Girard, P.
    O'shaughnessy, J.
    Hoff, P.
    Van Cutsem, E.
    Blum, J.
    Zuideveld, K.
    Jorga, K.
    Fagerberg, J.
    Bruno, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 307S - 307S
  • [28] A hybrid data-driven and model-based approach for computationally efficient stochastic unit commitment and economic dispatch under wind and solar uncertainty
    Bhavsar, S.
    Pitchumani, R.
    Ortega-Vazquez, M. A.
    Costilla-Enriquez, N.
    INTERNATIONAL JOURNAL OF ELECTRICAL POWER & ENERGY SYSTEMS, 2023, 151
  • [29] Longitudinal Model-Based Meta-Analysis of Lung Function Response to Support Phase III Study Design in Chinese Patients With Asthma
    Yang, Shuying
    Simeoni, Monica
    Beerahee, Misba
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (06) : 1286 - 1295
  • [30] Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150
    Bruno, Rene
    Marchand, Mathilde
    Yoshida, Kenta
    Chan, Phyllis
    Li, Haocheng
    Zou, Wei
    Mercier, Francois
    Chanu, Pascal
    Wu, Benjamin
    Lee, Anthony
    Li, Chunze
    Jin, Jin Y.
    Maitland, Michael L.
    Reck, Martin
    Socinski, Mark A.
    CLINICAL CANCER RESEARCH, 2023, 29 (06) : 1047 - 1055